A Tumor-Agnostic NTRK (TRK) Inhibitor - PubMed (original) (raw)
Review
A Tumor-Agnostic NTRK (TRK) Inhibitor
Franklin W Huang et al. Cell. 2019.
Free article
Abstract
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Copyright © 2019 Elsevier Inc. All rights reserved.